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The highly anticipated 2016 China Cancer Immunotherapy Workshop
held on June 25–26, 2016 in Beijing, China was a huge success. Built
on the overwhelmingly positive feedback from the 2015 China Can-
cer Immunotherapy Workshop, this event continued the tradition of
being the leading forum for delivering authoritative and updated
knowledge on the rapidly evolving field of immuno-oncology. The
workshop represented the ongoing collaboration among three orga-
nizations: China Center for Food and Drug International Exchange
(CCFDIE), the Center for Drug Evaluation (CDE) of the China Food
and Drug Administration (CFDA), and the Chinese American
Hematologist and Oncologist Network (CAHON).
Recent years have witnessed rapid and explosive developments in
cancer immunotherapy which has been viewed as a “historic break-
through” in cancer medicine. Scientists and physicians are engaged
at the incredible pace in discovery and clinical development of new
cancer immunotherapeutic agents. Patients eagerly expect more
options for immunotherapy and they anticipate significant clinical
benefit, even cure. In the meantime, these new advances and chal-
lenges necessitate physicians, scientists, and regulators to work
together in an unprecedented way to learn and keep abreast of the
latest developments in the field.
World-leading experts from academia, regulatory agencies and indus-
tries shared their views and experiences in several thematic areas,
organized into the following seven sessions: (1) basic immunology
and cancer immunology; (2) clinical updates on checkpoint inhibitors;
(3) emerging new immunotherapy; (4) perspective from industry; (5)
clinical updates on cellular therapy; (6) unique clinical development
considerations; and (7) regulatory considerations. As a result of
demand from conference participants, the conference organizers
decided to publish the proceedings of the meeting to benefit a
broader readership of the Journal of Hematology and Oncology on
the topic. Abstracts of all presentations are included except talks in
Session 4 which highlighted the immune-oncology pipelines of the
following biotechnology and pharmaceutical companies: Bristol-© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeMyers Squibb, Merck, Roche/Genetech, AstraZeneca, Merck Sereno,
Pfizer, Amgen, BeiGene, Henri, JW Biotechnology and InnoVent. The
information is publically available in their respective websites.
Session 1: Basic Immunology and
Cancer Immunology
A2
Set the stage: fundamental immunology in forty minutes
Zihai Li (zihai@musc.edu)
Department of Microbiology and Immunology, Hollings Cancer Center,
Medical University of South Carolina, Charleston, SC, USA
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The immune system in mammals is a hard-wired defense mechanism
that has co-evolved with the host to defend against pathogens, his-
toincompatible antigens and altered ‘self’ as a result of malignant
transformations and other damages. Functionally, the immune sys-
tem is often considered to have the innate and the adaptive arms.
Composed of physical barriers such as the skin and gut mucus layer,
as well as lytic enzymes, cytokines, and phagocytic cells such as mac-
rophages and dendritic cells, innate immunity is a built-in system
ready for immediate actions against pathological insults without the
need for pre-sensitization. The receptors to activate the innate im-
munity such as Toll-like receptors, Nod-like receptors and cytosolic
DNA sensors are germline-encoded gene products that can
recognize a broad range of shared molecular moieties in the patho-
gens or damaged tissues. T and B lymphocytes are key cell types in
the adaptive immunity that have exquisite mono-specificity (clonal-
ity) against antigens due to unique clonal receptors on their surface
generated from gene recombination at the somatic level. The forma-
tion of antigen receptors by gene recombination ensures the devel-
opment of a diverse repertoire of T and B cells for recognizing
practically all possible antigens. Depending on expression of the co-
receptor molecules CD4 and CD8, T cells can be divided into CD4+
and CD8+ cells which recognize peptide antigens in association with
MHC class II and class I molecules respectively. A key function of CD4
+ cells is to help CD8+ cells to attain effector functions (such as cyto-
toxicity) and assist B cells to differentiate into plasma cells and make
immunoglobulins (including five Ig isotypes: IgG, IgA, IgD, IgM and
IgE) that recognize antigens directly without the need for MHC mole-
cules. One hallmark of T and B cells is that they can be programed
into memory cells, which mount a greater response upon secondary
exposure to the same antigens. Importantly, innate and adaptive im-
munity do not operate in isolation. Recent exciting progress in fun-
damental immunology has uncovered the following guiding
principles of immunology that are particularly relevant for clinical
translation in oncology: (1) The activation of innate immunity, par-
ticularly dendritic cells, is often the prerequisite for initiation of adap-
tive immunity, which is the reason why adjuvant is needed for
optimal vaccinations. (2) Depending on the quality of the innate sig-
nals, adaptive immunity can adopt a distinct functional fate, favoringle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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etc.). (3) Adaptive immunity must always be kept in check by both
central and peripheral tolerance mechanisms such as negative check-
point signals and regulatory T cells due to the inherent risk of the
adaptive immunity to inflict autoimmunity. (4) Cancers or chronic in-
fectious agents take advantage of tolerance mechanisms to evade
the host immune defense. In short, it is ripe to harness the immune
system for combating human diseases due to increasing understand-
ing of the mechanisms that govern several laws of the system: diver-
sity, tolerance, memory and appropriateness.
A3
What have we learnt from the anti-PD-1/PD-L1 therapy of
advanced human cancer?
Lieping Chen (lieping.chen@yale.edu)
Yale University, New Haven, CT, USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A3
Immune responses are tightly controlled by cell surface immune
modulatory molecules that constitute various receptors and ligands
and could positively or negatively influence the quality and even the
direction of immune responses. The PD-1/PD-L1 immune modulatory
pathway plays important roles in suppressing antigen-specific im-
mune responses and inflammation. Selective expression of PD-L1
(B7-H1) in tumor microenvironment and subsequent interaction with
PD-1 on tumor-infiltrating T cells is demonstrated to be a major
mechanism of losing T cell immunity in tumor sites in a significant
fraction of cancer patients, a mechanism called adaptive resistance.
Monoclonal antibodies blocking this pathway have been tested
broadly worldwide and induced regression of a broad spectrum of
advanced human cancers especially solid tumors. The treatment is
well-tolerated and the clinical responses could be long-lasting. In the
context of ongoing large-scale clinical trials in thousands of cancer
patients, understanding of immunological mechanisms underlying
response and resistance to anti-PD-1/PD-L1 therapy is critical for fur-
ther improvement of cancer therapy in the future. I will discuss prin-
ciples of anti-PD-1/PD-L1 therapy and perspectives on cancer
therapy using this immune modulation approach.
Disclosure: Scientific advisory board-Pfizer, AstraZeneca, Johnson &
Johnson, NextCure; GenomiCare; Research funding- Boehringer Ingel-
heim, Pfizer, NextCure.
Session 2: Clinical Updates on
Checkpoint Inhibitors
A4
Immune checkpoint inhibitors in lung cancer
Edward B. Garon (egaron@mednet.ucla.edu)
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A4
Immune checkpoint inhibitors have rapidly become an established
therapy for patients with non-small cell lung cancer (NSCLC). In the
United States, two inhibitors of the programmed cell death 1 (PD-1)
immune checkpoint, nivolumab and pembrolizumab, are approved
for the treatment of previously treated NSCLC. Each drug has an ap-
proved diagnostic test for the PD-1 ligand PD-L1. The role of PD-L1
testing remains controversial, not necessarily based on doubts as to
whether high PD-L1 levels enhance the likelihood of benefit from
PD-1 inhibitors in non-squamous NSCLC, but rather whether patients
with low or absent staining should still get PD-1 inhibitors in light of
available alternate approaches in previously treated NSCLC. Although
potential differences in the PD-L1 tests have been a concern to date,
recent studies have shown strong similarity for the available tests in
NSCLC specimens. Data is also evaluating a host of alternate and/or
complementary biomarkers in addition to PD-L1. Emerging data is
assessing the role of several PD-L1 inhibitors in NSCLC. In addition,
emerging data is evaluating inhibitors of the PD-1 checkpoint in a
variety of NSCLC clinical settings, including frontline therapy for
metastatic disease, adjuvant therapy, and consolidation therapy afterchemoradiotherapy for locally advanced disease. There is also emer-
ging data in small cell lung cancer, although the number of patients
evaluated to date is relatively small. The role of inhibitors of other
immune checkpoints in lung cancer are less certain to date. Many
clinical trials evaluating alternate checkpoint inhibitors or combina-
tions of inhibitors of the PD-1 checkpoint with inhibitors of other
checkpoint are underway. The combination of inhibitors of the PD-1
checkpoint and cytotoxic T-lymphocyte associated protein 4 (CTLA-4)
have been the most extensively evaluated combination to date, with
data that is promising, but limited by additional toxicity, small num-
bers of patients in non-randomized studies and inconsistent results
with respect to the role of PD-L1 in predicting which patients will
benefit.
A5
Mechanisms of response and resistance to checkpoint inhibitors in
melanoma
Siwen Hu-Lieskovan (shu-lieskovan@mednet.ucla.edu)
University of California at Los Angeles, Los Angeles, CA, USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A5
Recent breakthrough in immunotherapy for cancer provides poten-
tial of long lasting benefit to patients with melanoma and a wide
array of other tumor subtypes. Inhibiting adaptive immune resistance
is the mechanistic basis of the antitumor activity of PD-1 immune
checkpoints blockade therapies, by releasing the breaks or unleash-
ing the immune system in patients whose immune system was ready
to attack the cancer but was being blocked by the cancer. Combin-
ation therapies to increase the priming of T cells and overcome the
immune-suppressive tumor microenvironment are being developed
to increase the benefit to more tumor types and patients. Engineer-
ing the immune system for adoptive cell transfer (ACT) therapy is be-
ing developed to help patients who cannot mount a tumor specific
immune response. Genetic (and likely epigenetic) alterations leading
to crippled IFN-receptor signaling result in primary resistance to PD-1
blockade therapy. Loss of function mutations in IFN-receptor signal-
ing or antigen presenting machinery mediate acquired resistance to
PD-1 blockade therapy.
A6
Checkpoint inhibitor immunotherapy in lymphoid malignancies
Wei Ding (ding.wei@mayo.edu)
Hematology, Mayo Clinic. Rochester, MN, USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A6
The inhibitors of checkpoint pathways aiming to unleash the brake on
immune system have been tested in multiple solid tumors and have
revolutionized cancer therapy in the last five-ten years. However, the
clinical trials of testing checkpoint inhibitors in hematological malignan-
cies have just been initiated and are still in their infancies. Recent early
phase trials of testing PD-1 blocking antibody nivolumab or pembroli-
zumab in relapsed and refractory hodgkin’s lymphoma have revealed
robust clinical response with an estimated overall response rate 65-
85 %. However, the single- agent response rate of PD-1 blockade in
multiple subtypes of non-Hodgkin’s lymphoma (NHL) was only 10-
40 %. The etiology of these differential responses has just been partially
elucidated. Genetic alterations causing amplification or translocation of
chromosome 9p24.1 where PD-L1 and PD-L2 genes are located have
been detected in classical hodgkin’s lymphoma and primary medias-
tinal large B cell lymphoma. Expression of PD-L1 are also present in
multiple types of other NHL including T cell rich large cell lymphoma,
post-transplant lymphoproliferative disorder, EBV positive lymphoma
including diffuse large B cell lymphoma. Studies focusing on dissecting
tumor microenvironment in lymph nodes have revealed complex inter-
actions and differential bias of T cell immunity in different subtypes of
lymphoma. Biomarkers that can predict clinical response of PD-1 block-
ade are needed in many types of lymphomas. Further combination
therapies of signal inhibitors with immunotherapy are intensely studied
in the ear of novel immunotherapy to improve clinical efficacies.
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Translational research to improve the efficacy of immunotherapy
in genitourinary malignancies
Chong-Xian Pan (cxpan@ucdavis.edu)
Department of Internal Medicine and Urology, University of California
Davis Comprehensive Cancer Center, Sacramento, CA, USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A7
Immunotherapy with checkpoint inhibitors has shown promising ac-
tivity in genitourinary malignancies. In kidney cancer, the anti-
Programmed Death 1 (PD1) antibody nivolumab has been approved
by the US Food and Drug Administration (FDA) to treat patients with
metastatic renal cell carcinoma after progression on an antiangio-
genic therapy. The anti-tumor activity can be seen in both PD1-
positive and PD1-negative kidney cancers. In prostate cancer, even
though Sipuleucel-T is approved for the treatment of castration-
resistant metastatic prostate cancer with minimal or no symptoms,
its treatment is not associated with any improvement of clinical or
objective progression-free survival or prostate-specific antigen (PSA)
reduction. In urothelial cancer, an anti-programmed death ligand 1
(PD-L1) antibody atezolizumab has been approved for the treatment
of patients with locally advanced or metastatic urothelial carcinoma
whose disease has worsened during or following platinum-
containing chemotherapy, or within 12 months of receiving
platinum-containing chemotherapy, either before (neoadjuvant) or
after (adjuvant) surgical treatment. However, only a minority of blad-
der cancer patients benefit atezolizumab. PD-L1 expression, luminal
subtype II and high mutation load are associated with higher re-
sponse rate to atezolizumab. Nevertheless, cancer response is also
observed in cancer with absence of PD-L1 expression, other urothe-
lial cancer subtypes and low mutation load. In addition to the above
mentioned agents, several other checkpoint inhibitors have also
showed anti-tumor activity. Many clinical trials are currently going to
determine whether the efficacy of immunotherapy can be improved
by combining a checkpoint inhibitor with other immunoregulatory
agents, chemotherapy, radiation therapy or targeted therapy.
Despite the above mentioned great achievement, lack of appropriate
animal models hinders research in immunotherapy. To address this
issue, University of California Davis and The Jackson Laboratory have
collaborated to establish humanized mice carrying patient-derived xe-
nografts (PDXs). Humanized mice were generated and human immune
system was reconstituted after injection of human hematopoietic cells
into immunodeficient NSG mice. PDXs were developed after implant-
ation of uncultured tumor specimens from human patients into NSG
mice. PDXs retained the morphology fidelity and 92-97 % genetic alter-
ations of parental patient cancers. Humanized mice carrying urothelial
cancer PDXs responded to an anti-PD1 antibody pembrolizumab simi-
lar to that observed in clinical patients. Treatment of pembrolizumab
was associated with infiltration of CD45 + CD8+ human T cells in PDXs.
Other molecular correlative studies are currently going on. In order to
improve the treatment of urothelial cancer, we developed urothelial
cancer-specific porphyrin-based nanoparticles. These cancer-specific
nanoporphyrin can be used for targeted chemotherapy, radiation ther-
apy, photodynamic therapy and photothermal therapy. Research is
currently being performed to determine whether these targeted ther-
apies with cancer-specific nanoporphyrin can improve the efficacy of
immunotherapy.
A8
Immune checkpoint inhibitors in gastrointestinal malignancies
Weijing Sun (sunw@upmc.edu)
University of Pittsburgh Cancer Center, Pittsburgh, PA, USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A8
Gastrointestinal (GI) malignancies are highly aggressive and hetero-
geneous diseases. The overall outcomes of advanced and metastatic
GI malignancies are still very disappointing with the current chemo-
therapy options. Target-oriented agents have only showed moderate
effectiveness. Although the attempt of immunotherapy has been for
many years, it is not only until very recent years that the clinicallyencouraging results begun to emerge, primarily in the areas of im-
mune checkpoints blockade against PD-1/PD-L1 and CTLA4 in man-
agement of GI cancers.
Microsatellite instability (MSI) plays a significant role in the GI can-
cers’ formation and development, and is characterized by deletion or
mutations of DNA mismatch repair (MMR) genes (e.g., Mlh1, Msh2,
Pms1 and Pms2), or the hypermethylation of the promoters of the
genes (e.g., Mlh1). The high mutational load in MSI (MMR-deficiency)
tumors are therefore associated with high level of tumor-specific
neoantigens, which are frequently recognized by the immune sys-
tem. A phase II study showed a good activity of pembrolizumab, an
anti-PD-1 monoclonal antibody in patients with chemotherapy-
refractory metastatic GI malignancies with MSI. Furthermore, a recent
reported interim data analysis of the study (Checkmate 142) showed
the advantage of combining the anti-PD-1 monoclonal antibody
(Nivolumab) with anti-CTLA monoclonal antibody (Ipilimumab) in
MMR-deficient colorectal cancer over anti-PD-1 alone. The efficacy of
anti-PD-L1 in combination with MEK inhibitor showed very encour-
aging results in Kras muted metastatic colorectal cancer.
Based on the classification by the Cancer Genome Atlas (TCGA) pro-
ject, four major molecular subtypes are recognized in gastric cancer:
chromosomally unstable, Epstein Barr Virus (EBV)-infection related,
MSI-associated, and genomically stable disease. In the EBV-infection
related subgroup, PD-L1 and PD-L2 are upregulated due to chromo-
some 9p24 amplification. Therefore, blockading the PD-1 or PD-L1/
PD-L2 in this subgroup is likely to create recognizable antitumor ac-
tivity. Efficacy of anti-PD-I monoclonal antibodies (nivolumab or pem-
brolizumab) has been demonstrated in patients with advanced/
metastatic esophageal and gastric cancer with or without PD-L1 ex-
pression (Keynote-012, Keynote-028 and CheckMate-032). More stud-
ies are ongoing at phase II and III levels in different settings.
Hepatocellular microenvironment is characterized by immunosup-
pression with PD-L1 expression on Kupffer cells and on sinusoidal
endothelial cells. Preliminary phase I study data suggested very en-
couraging results of nivolumab in the treatment of patients with ad-
vanced hepatocellular carcinoma (HCC) with various etiology,
including those caused by alcohol and viruses (both hepatitis B and
C viruses).
In summary, immune therapy has shown encouraging results in the
treatment of GI malignances and likely has a bright future. Current
evidences are derived mainly from the immune checkpoint blockade
monotherapy. Future studies are warranted in testing immune check-
point blockers in combination with chemotherapy, targeted agents,
as well as other immunotherapeutic strategies.
Session 3: Emerging New
Immunotherapy
A9
What’s next beyond PD-1/PDL1?
Yong-Jun Liu (yong-jun.liu@sanofi.com)
Head of Research, Global R&D, Sanofi, Paris, France
Journal of Hematology & Oncology 2016, 9(Suppl 1):A9
The current excitement of immuno-oncology stems from decades
of basic research in immunology. There are five essential steps to
elicit effective anti-cancer T cell immunity: (1) tumor antigen
presentation by dendritic cells (DCs); (2) priming of naïve T cells
by immunogenic DCs; (3) egress of effector T cells from the sec-
ondary lymphoid organs; (4) infiltration of tumors by tumor-
specific T cells; and (5) eradication of tumors by effector mechan-
ism of T cells. Thus rational strategies are being developed for
cancer immunotherapy to boost each of the five processes. I will
discuss especially two areas of research in my laboratory. The
first has to do with our discovery of plasmacytoid dendritic cells
(pDCs) which is a key cell type in conferring anti-viral immunity
and therefore plays critical roles in immune surveillance against
viral associated malignancies. The second line of investigation
deals with regulatory T cells via blocking OX40 receptor. We have
generated a monoclonal antibody against OX40. This antibody
has been shown to inhibit the immunosuppressive function of
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(“Tr1 cells”) and Foxp3 + −expressing regulatory T cells. Clinical tri-
als are ongoing with this agent. Thus, it is abundantly clear that
the field of immuno-oncology will continue to move forward rap-
idly beyond PD-1/PD-L1 checkpoints.
A10
Cancer vaccines: new insights into the oldest immunotherapy
strategy
Lei Zheng (lzheng6@jhmi.edu)
1Department of Oncology and Surgery, The Sidney Kimmel
Comprehensive Cancer Center, Johns Hopkins University School of
Medicine, Baltimore, Maryland; 2Skip Viragh Center for Pancreatic Cancer,
Johns Hopkins University School of Medicine, Baltimore, Maryland;
3Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins
University School of Medicine, Baltimore, Maryland; 4Graduate Program
in Cellular and Molecular Medicine, Johns Hopkins University School of
Medicine, Baltimore, Maryland
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Immunotherapy is considered to be one of the breakthroughs
for cancer treatments in the last decade, attributed to the de-
velopment of immune checkpoint inhibitors. The first immuno-
therapy was conducted by Dr. William Coley in 1891 by using a
cancer vaccine-like strategy. Nevertheless, the recent results of
the clinical trials with cancer vaccine approaches are disap-
pointing. Multiple layers of immune tolerance mechanisms have
made the cancer vaccine strategy fail to induce adequate anti-
tumor response. On another hand, more than half of the cancer
patients do not respond to the single agent immune check-
point inhibitors due to lack of effector immune cells infiltrating
the tumors. Cancer vaccine treatments may prime the immune
quiescent tumors with the infiltration of effector immune cells,
which also induce the immune checkpoint signals including PD-
1/PD-L1 presumably through adaptive resistance mechanisms.
The combination of vaccine and immune checkpoint inhibitors
may overcome the resistance to the immune checkpoint inhibi-
tors as a single agent treatment. Immune checkpoint inhibitors
achieve the anti-tumor activity by unleashing response to tumor
neoantigens, suggesting that cancer vaccines that target neoan-
tigens could be more potent. Neoantigens-based cancer vac-
cines are being developed. In addition, oncolytic virus has been
shown to induce immunogenic tumor lysis and can also be
employed as a vaccine strategy to induce the immune response
to cancer neoantigens. Finally, the combination immunotherapy
is the key to the success in making more and more patients
benefit from the immunotherapy.
Disclosure: GVAX – Under a licensing agreement between Aduro Bio-
Tech, Inc. and the Johns Hopkins University, the University and in-
vestigators (L.Z.) are entitled to milestone payments and royalty on
sales of the vaccine product. L.Z. served in the advisory board for
Halozyme: advisory board, and received the research grant from
Halozyme, BMS, Merck, and iTeos. L.Z. is a paid consultant at
Percans and Lifemax.
A11
Bispecific antibodies for cancer immunotherapy
Delong Liu (delong_liu@nymc.edu)
New York Medical College and Westchester Medical Center, Valhalla, NY,
USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A11
Immune checkpoint blockers and CAR-T immunotherapeutic
modalities are revolutionizing cancer treatment. Bispecific anti-
bodies offer additional treatment options as cancer immuno-
therapy [1]. Bispecific T cell engager (BiTE) antibodies are
entering clinical applications for pre-B acute lymphoid leukemia
(blinatumomab) and certain EpCAM+ solid tumors (catumaxo-
mab) [2–4]. More and more bispecific antibodies are in activeclinical development. AFM11, a tetravalent BiTE antibody against
CD19 and CD3, is being explored for B cell malignancies.
AFM13 with bispecificity toward CD30 and CD16A is pushing NK
cells into the field of cancer immunotherapy. AFM13 is tetrava-
lent, and has a longer half life than bivalent BiTE antibodies [5].
Specifically, 28 patients with highly refractory Hodgkin lymph-
oma have been treated in a phase I trial [6]. Dose limiting tox-
icity with hemolytic anemia was reported in one patient. Newer
technology in antibody design and production make it possible
for rapid development of novel antibodies for clinical
application.
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Session 5: Clinical Update on Cellular
Therapy
A12
Updates on CAR-T immunotherapy
Michel Sadelain (m-sadelain@ski.mskcc.org)
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center,
New York, NY, USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A12
T cell engineering provides a means to rapidly generate thera-
peutic T cells of any specificity. This novel therapeutic modality is
predicated on the transduction of receptors to redirect T cell spe-
cificity and enhance T cell function. Chimeric antigen receptors
(CARs) are synthetic receptors that mediate antigen recognition, T
cell activation, and, in the case of second generation CARs, costi-
mulation. We demonstrated over a decade ago that human T
cells engineered with a CD19-specific CAR eradicated B cell ma-
lignancies in mice, and we were the first to report remarkable
complete remission rates obtained with second generation CD19
CARs in adults with chemorefractory, relapsed acute lympho-
blastic leukemia. We have by now infused over 50 patients at
our center, who were treated with a single infusion of autologous
T cells expressing the 19-28z CAR. The complete response rate is
in the 80-90 % range, with over 80 % achieving a molecular re-
sponse. Within the latter, the estimated 6-month overall survival
rate for the minimal (<5 % blasts) and morphologic disease pa-
tients (≥5 % blasts) were 92 % and 65 %, respectively, with re-
missions extending beyond 3 years in the minimal disease
cohort. Several groups, including ours, have extended these re-
sults to other B cell malignancies including non-Hodgkin lymph-
oma, pediatric ALL and chronic lymphocytic leukemia. CAR
toxicities include B cell aplasia, cytokine release syndrome (CRS)
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auto- and trans-costimulation and combinatorial antigen recogni-
tion, hold the promise of further enhancing the effectiveness and
safety of CAR therapy against a broad range of cancers. The suc-
cess of CD19 CAR therapy has generated unprecedented enthusi-
asm for cell-based therapies, which urgently require the
development of more performing and safe manufacturing pro-
cesses to meet the anticipated demand for autologous and alter-
native T cell products.Fig. 1 (abstract A13). Endogenous T Cell (ETC) therapyA13
Adoptive T cell therapy: personalizing cancer treatment
Cassian Yee (cyee@mdanderson.org)
Department of Melanoma, MD Anderson Cancer Center, Houston, TX,
USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A13
Adoptive cellular therapy (ACT) represents an increasingly attract-
ive treatment for patients with cancer because of the potential
for significant anti-tumor efficacy, minimal toxicity and longterm
immunoprotection. We have been exploring one form of ACT,
known as endogenous T cell (ETC.) therapy Endogenous T cell
(ETC.) therapy exploits enabling technology developed in our lab
to isolate rare (<1:100,000) antigen specific T cells from the per-
ipheral blood and render them, by IL-21 exposure during priming,
to become helper-independent, antigen-driven autocrine central
memory type T cells with high replicative capacity and longterm
in vivo persistence.
To overcome potential barriers to effective ACT, a means to en-
hance the duration and efficacy of transferred T cells, modulate
and/or eradicate Tregs and lower the threshold of activation of
endogenous tumor-reactive effectors would be desirable. We re-
port here the use of a first-in-human adoptive cellular therapy
regimen combining the use of IL-21-primed antigen-specific T
cells, with a post-infusion course of anti-CTLA4 therapy that can
yield long-lasting, and significant clinical responses with min-
imal toxicity (Chapuis & Yee et al., JEM 2016 and JCO 2016).
One major challenge however to advancing the use of ACT for
solid tumor malignancies in general is a lack of knowledge of
the MHC-restricted peptides presented on individual patient tu-
mors that can be targeted with T cells, and, a means of rapidly
deploying antigen-specific adoptive cellular therapy strategy fol-
lowing identification of such immunogenic peptides. Our re-
search group has been focused on developing antigen-specific
T-cell based immunotherapies for the treatment of cancer pa-
tients [1].
First, by employing a combination of next generation sequen-
cing, mass spectrometry-based proteomics, and HLA bioinfor-
matics, we have developed a highly sensitive tumor antigen
identification method that can reliably identify HLA-bound pep-
tide ligands presented by cancer cells from individual patients
[2]. Second, we have developed enabling technologies that
allow us to successfully isolate and enrich from the endogenous
T cell population in patient peripheral blood - rare, tumor
antigen-specific T cells recognizing these potential immuno-
genic epitopes. In preliminary studies, we have routinely gener-
ated CTLs specific for tumor antigens identified through our
antigen discovery pipeline, and demonstrated anti-tumor activ-
ity against HLA-matched tumor cell lines. In contrast to TIL
therapy or CAR/TCR-engineered T cells, ETC. therapy provides
the expediency and flexibility required to generate T cells
against individualized neo-epitopes identified ad hoc from pa-
tient tumor samples. We propose to develop personalized,
antigen-specific adoptive T cell therapy for patients using this
immunopeptidome pipeline and tetramer-guided cell sorting for
patients with solid tumor malignancies using a combined ACT +
ICI outpatient regimen that has already demonstrated in early
studies to be safe, effective, and offers longterm protection
from relapse.A14
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Harnessing the immune system to eradicate malignant cells is becoming
a powerful new approach to cancer therapy. Immunotherapy-based
drugs, including anti-CTLA-4, anti-PD-1 and anti-DP-L1antibodies, have
been approved for the treatment of many types of cancer. Furthermore,
recent clinical trials using antigen-specific T cell receptor (TCR), or CD19-
chimeric antigen receptor (CAR), have shown promising clinical results for
patients with metastatic cancer. Identification and clinical evaluation of
new checkpoint signaling molecules are the major focus for developing
new therapeutic drugs. Because these immunotherapies rely on tumor-
specific T cells to fight against cancer, recruitment and trafficking of
tumor reactive T cells to tumor sites and their persistence have become
the one of the most active and fast-moving research areas. For TCR and
CAR T cell therapy, the choice of cancer antigens recognized by T cells is
pivotal to success of cancer immunotherapy. Despite significant progress
in cancer antigen discovery, there are only very few targets that have
been demonstrated to mediate clinical response and tumor regression
without evident toxicity. NY-ESO-1 is one of such cancer antigens that
show the promising clinical activity. NY-ESO-1-specific TCR-engineered T
cells have produced 55-80 % of clinical response in metastatic sarcoma,
melanoma and myeloma. A key question is how to identify many more
immune targets that are suitable for cancer immunotherapy using TCR or
CAR technologies for different types of cancer. With recent technology
advances in next-generation sequencing, it become possible to dissect
the immune response to patient-specific mutated antigens, which may
be critical in mediating tumor-specific immune response against cancer.
Understanding of these mutated and nonmutated antigens is critical for
the development of novel personalized immunotherapy and precision
medicine. I will present the latest findings and discuss the current pro-
gression and future directions in cancer immunotherapy.
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The Author(s) Journal of Hematology & Oncology 2016, 9(Suppl 1):104 Page 6 of 8CD133 is well-documented to be expressed by tumor initiating cells
and epithelial progenitor cells, which were proposed to have pre-
dominant roles for tumor recurrence and pre-metastatic niche forma-
tion, respectively. Thus, targeting CD133 might help eradicate the
primary tumors and even prevent tumor metastasis. Herein, CD133-
directed chimeric antigen receptor modified T cells (CART-133) were
successfully generated and their marked antitumor activity was veri-
fied. Results from hematopoietic colony forming assays suggested
that CART-133 cells may pose no irreversible myelosuppression. From
October of 2015 to February of 2016, 10 patients with advanced and
sorafenib-refractory hepatocellular carcinoma (HCC) were enrolled on
phase I trial and were assigned into 3 dose-escalated cohorts (ac-
cording to CART-133 positive cell amount: 0.10-1.0 × 106/kg, 2-5 ×
106/kg, and 0.5-1.0 × 107/kg). 8 out of 10 patients received CART-133
monotherapy once or repeated infusion every 4–8 weeks. Patients
who received CART-133 infusion were assessed for response. All
patients had tolerable febrile syndromes during cell infusions. Of
consecutively enrolled patients, rapid ascites growth occurred in 1
patient during infusion and was reversible by the use of diuretic, and
1 patient developed transiently drastic decline of hemoglobin and
platelets and Grade 3 direct hyperbilirubinemia within 2 weeks after
cell infusion. Reverse correlation between CD133+ cells in peripheral
blood and CAR copy number in cohort 2 and 3 revealed an effective
biological activity and safety of CART-133 and its rational expansion
dose. 1 of 3 cases in cohort 1 aggressively progressed after cell ther-
apy and became stable after transferred to cohort 2. Seven cases
maintained stable disease as of the most recent follow-up, however,
2 patients died of upper gastrointestinal massive hemorrhage
>9 weeks after infusion. On the basis of the presented data, add-
itional 13 patients (5 sorafenib refractory HCCs, 5 advanced/meta-
static pancreatic carcinomas, 2 metastatic colorectal carcinomas, and
1 advanced cholangiocarcinoma) were recruited into phase II trial
using the expansion dose so far. All toxicities associated with the cell
therapy even in those who received chemo-combined regimens with
multiple cycle CART-133 infusions were controllable. The clinical re-
sponse evaluation of all these patients in phase 2 is still ongoing.
This study demonstrated the safety, feasibility, and preliminarily clin-
ical efficacy of CART-133 treatment in epithelium-derived solid tu-
mors, and guaranteed further patient recruitment. This clinical trial is
registered at www.clinicaltrials.gov as NCT02541370.
All authors declare that they have no competing interests. Correspondence
to: Weidong Han, MD, PhD, Department of Molecule & Immunology/Bio-
therapeutic Department, Chinese PLA General Hospital, Beijing, 100853,
China. E-Mail: hanwdrsw@sina.com. or hanwdrsw69@yahoo.com
Session 6: Unique Clinical Development
Considerations
A16
Cancer immunotherapy biomarkers: progress and issues
Lisa H. Butterfield (butterfieldl@upmc.edu)
University of Pittsburgh, Pittsburgh, PA, USA
Journal of Hematology & Oncology 2016, 9(Suppl 1):A16
Biomarkers that can 1) predict which patient should be enrolled in a
clinical trial or receive a treatment; 2) prognosticate early on treat-
ment whether a patient is receiving benefit from therapy; or 3) iden-
tify the mechanism of action of a therapeutic intervention are
critically needed in immunotherapy for cancer. Because immunother-
apy involves manipulation of a complex network of cells and mole-
cules throughout the body (and not changing the function of a
single protein), identification of these biomarkers is difficult. Despite
many years of use of interferon and IL-2 in melanoma and other can-
cers, the patients who can and will benefit and the exact mechanism
of action is still not known. Importantly, research lab-based and
retrospective biomarker studies are further complicated by lack of
standardization of patient blood and tumor sample processing and
storage. There are many candidate biomarker assessments that have
given useful and important data regarding patient outcomes, includ-
ing testing tumor-specific T cell frequencies and T cell activation, and
suppressive cell measures (including regulatory T cells (Treg) andmyeloid-derived suppressor cells (MDSC)), in blood and in tumors. In
some cases, phenotypic measures without functional testing can give
conflicting results. Newer molecularly-based assays of tumor muta-
tion load, T Cell Receptor (TCR) diversity and tumor inhibitory mol-
ecule expression (like PD-L1 staining) are giving interesting signals
that require further investigation in multiple tumor settings and at
multiple time points to further substantiate. The Society for Immuno-
therapy of Cancer (SITC) has lead several initiatives over the last
15 years in immunologic monitoring in cancer. Most recently, the
Immunoscore task force has completed their work, and the Immuno-
logic Biomarkers Task Force have prepared white papers on the state
of the art, hurdles in the field and recommendations for the future
that are now being published to help the field progress in the identi-
fication of these important biomarkers.
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AstraZeneca
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Immune checkpoint blockade is a promising approach for the treat-
ment of human malignancies. For example, treatment of patients
with advanced lung cancers and melanoma have resulted in im-
proved response rates and durable disease control. However, the ex-
tent to which patients derive benefit is diverse and the determinants
that drive response to therapy are ill-defined. We have sought to de-
fine the genomic determinants of response to immune checkpoint
blockade therapies such as anti-CTLA-4 and anti-PD-1. Our work has
shown that tumor mutational burden, clonality, and mutational land-
scape features help dictate clinical response. Mutations in genes that
are part of the antigen presentation machinery are rare but can be
preferentially downregulated in tumors. Reexpression of genes in the
MHC antigen presentation pathway by treatment with epigenetic
therapy synergizes with immune checkpoint blockade to boost anti-
tumor responses.
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Cancer immunotherapy has progressed very rapidly in the past few
years, with the potential to transform future new standard of care in
oncology due to its unique science and its potential for substantial
and long-term clinical benefit. The success is based on the progress
in both preclinical and clinical science, including the development of
new paradigm of clinical investigation. As the target of immunother-
apy is not directly attacking the tumor but instead mobilizing the
host immune system, the unique development consideration (study
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Therapy with immune checkpoint inhibitors has revolutionized can-
cer therapy. In the United States, four checkpoint inhibitors (nivolu-
mab, pembrolizumab, atezolizumab and ipilimumab) have been
approved for patients with previously treated melanoma, RCC, NSCLC
The Author(s) Journal of Hematology & Oncology 2016, 9(Suppl 1):104 Page 7 of 8and bladder cancer. Clinical data also shows that the programmed
cell death 1 (PD-1) immune checkpoint inhibitor nivolumab has a
better safety profile than anti-CTLA-4 ipilimumab. However, all cur-
rently approved checkpoint inhibitors when used as single-agent
therapy only result in modest clinical improvement in patients with
advanced disease. In this presentation, several topics will be dis-
cussed: 1. opportunities and challenges of immune checkpoint inhibi-
tors for cancer treatment; 2. basic principles of cancer immune
checkpoint inhibitor combination therapies; 3. future for cancer
immunotherapies.
Many clinical trials evaluating different combination therapies are un-
derway to determine if combinations can significantly improve over-
all response and long term survival in cancer patients.Fig. 2 (abstract A19). Principle of cancer immune checkpoint
inhibitor combination therapiesA20
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PD-1inhibitors are approved to treat lung cancer and anti-PD1 ther-
apy is poised to become a major front-line treatment for lung cancer.
Integrating PD-1 inhibitors into radiotherapy regimens potentially
breaks immune tolerance against lung cancer cells and synergistically
activates T cells. However, it is not clear how these two modalities
should be optimally combined. We have established novel mouse
models that allow us determine the appropriate radiotherapy regi-
men and sequencing with anti-PD1 therapy. Similar questions are be-
ing addressed in an ongoing clinical trial. In addition, we
investigated potential toxicities when thoracic radiotherapy is con-
currently administered with anti-PD1 in a number of mouse models.
Activation of host immunity has the risk of enhancing radiation toxic-
ities in normal tissues. Both cardiac and pulmonary toxicity were re-
ported among patients receiving PD1 inhibitors. Both carditis and
pneumonitis are evident in the PD-1null mice. Thoracic radiotherapy
for patients with locally advanced lung cancer is associated with car-
diac and lung toxicities stemming from an immune/inflammatory re-
sponse. A number of reports including the analyses of the RTOG
0617 study suggested decreased survival in patients receiving more
radiation exposure to the heart. Our preliminary data from mouse
models demonstrated significantly increased acute death from thor-
acic or cardiac irradiation when PD-1 is absent or inhibited. We plan
to translate our findings into better-designed clinical trials of anti-
PD1 immunotherapy and radiotherapy for lung cancer.
Session 7: Regulatory Considerations
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The last decade (2006–2016) has witnessed tremendous advances in
cancer immunotherapy, illustrated by the increasing number of
immunotherapeutic products approved by US FDA. Out of 184 onco-
logical indications approved by US FDA, approximately one thirdindications were related to cancer immunotherapy [1]. The majority
of approved indications are from monoclonal antibodies, the main-
stay of the current hematologic and oncologic practices. The devel-
opment of these antibodies has evolved considerably: from simple
naked antibodies [2] to relatively complex conjugated antibodies [3],
to bi-specific T cell engager (BiTE) [4], and to checkpoint inhibitor
antibodies [5]. The latter two also redefine therapeutic monoclonal
antibodies from merely “passive” immunotherapy to active immuno-
therapy since their mechanism of action involves activation of en-
dogenous T cells. The approval for active immunotherapeutic agents
has also undergone historical changes: from cytokines such IL-2 and
interferon to more complicated cellular cancer vaccine [6] and onco-
lytic virotherapy [7]. Intensive efforts have been devoted to adoptive
T cell therapy and chimeric antigen receptor (CAR) T cell therapy, nei-
ther of which has been approved in the US. Adoptive T cell therapy
using tumor-infiltration lymphocyte (TIL) has been mainly studied in
the advanced melanoma with response rates of 30-60 % [8]. CAR T
cells have shown high response rates of 70-90 % in hematologic ma-
lignancies such as refractory or relapse acute lymphoblastic lymph-
oma (ALL) [9]. Challenges in the development of adoptive T cell
therapy include chemistry, manufacturing and control and clinical
considerations, such as study population, endpoint evaluation and
toxicity management. The advent of modern technologies such as
next gene sequencing has enabled cancer genome to be deciphered
and let to the identification of neoantigen unique to the tumor [10].
When treated with immunotherapy, patients with tumors harboring
more mutation load appear to have a better clinical outcome than
patients with less mutation load [11]. Adoptive transfer of TIL con-
taining mutation–reactive T cells could mediate the response of the
tumor harboring the cognate antigen [12]. Active clinical research
tests whether this approach as well as cancer vaccines based on the
neoantigens have advantages over the shared antigens [13]. The ap-
proval of ipilimumab with nivolumab for advance melanoma ushers
more venues for the power of immunotherapy [5]. More clinical re-
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Breakthrough Therapy designation is a regulatory program that was
introduced in Section 902 of the Food and Drug Administration
Safety and Innovation Act of 2012. Its objective is to expedite the de-
velopment and review of investigational products intended to treat
serious or life-threatening diseases, thereby improving patient early
access to novel effective treatments. Designation of a Breakthrough
Therapy is indication-based and requires preliminary clinical evidence
that demonstrates the intended therapy or investigational product
may provide substantial improvement over available or existing ther-
apies on one or more clinically significant endpoints.
The Author(s) Journal of Hematology & Oncology 2016, 9(Suppl 1):104 Page 8 of 8In oncology, 56 Breakthrough Therapies have been designated since
the program’s inception1. Of them, 21 are already approved for clin-
ical use. Six approved indications (28 %) are for immunotherapeutic
products, suggesting that immunotherapy plays an important role in
the Breakthrough Therapy program. For products approved between
2013 and 2015, median premarket development time was 2.2 years
shorter among approved Breakthrough-designated products (12)
than non-designated products (17)2. This preliminary analysis sug-
gests that this program has considerably improved patient early ac-
cess to novel effective cancer treatments.
Overall, the current evidence shows that Breakthrough Therapy des-
ignation has facilitated the development and review of novel effect-
ive oncology products, including immunotherapeutic products.
Together with other expedited programs3, it helps address existing
or emerging unmet medical needs in oncology. Most importantly,
this program along with Accelerated Approval4 may substantially
save time (e.g., 2–5 years earlier on average) for patients to access ef-
fective cancer treatments.
References
1. Breakthrough Therapies. Available at http://www.focr.org/breakthrough-
therapies. Accessed June 2016.
2. Shea M, Ostermann L, Hohman R et al. Impact of breakthrough therapy
designation on cancer drug development. Nature Review 2016; 15:152.
3. Guidance for Industry: Expedited Programs for Serious Conditions-Drugs
and Biologics, available at: http://www.fda.gov/downloads/drugs/guidan-
cecomplianceregulatoryinformation/guidances/ucm358301.pdf
4. Johnson JR, Ning YM, Farrell A, et al. Accelerated Approval of Oncology
Products. JNCI 2011; 103:1–9.
A23
Current European regulation of innovative oncology medicines:
opportunities for immunotherapy
Harald Enzmann1, Heinz Zwierzina2
1Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-
Allee 3, 53175 Bonn, Germany; 2Cancer Drug Development Forum -
CDDF Headquarters, c/o ECCO - Avenue E. Mounier 83, B-1200 Brussels,
Belgium
Correspondence: Harald Enzmann (harald.enzmann@bfarm.de) –
Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-
Allee 3, 53175 Bonn, Germany
Journal of Hematology & Oncology 2016, 9(Suppl 1):A23
In the European Union (EU) regulatory agencies change their assess-
ment procedures. The European Medicines Agency has instituted their
Adaptive Pathways concept and priority medicines (PRIME) scheme for
the early authorization of medicines (1). Early marketing authorization
(MA) applications using Adaptive Pathways are based on surrogateendpoints confirmed by clinical outcome data post-authorization or on
a selected subpopulation of most suitable patients for the initial appli-
cation, expanding the indication later by variation procedures. PRIME
will provide extensive regulatory support mostly in the presubmission
phase and is expected to be most helpful for small and medium sized
enterprises. Innovative oncology immunotherapies (IOI) are particularly
well-positioned to profit from these changes and qualify for PRIME and
adaptive pathways.
Regulators have become increasingly aware of the link between their
assessment and pricing (3). Subsequent to the MA, mostly national
decisions by Health Technology Assessment (HTA) bodies and payers
have become prerequisites for patients’ access to innovative medi-
cines. At variance with the Adaptive Pathways’ acceptance of surro-
gate endpoints HTA bodies put more emphasis on clinical outcome
data (4). Within the EU, divergent decisions on reimbursement result
in pronounced differences in patients’ access to innovative medi-
cines. In addition, the time between MA and actual market launch is
widely different between member states. The delay from MA to mar-
ket launch is shortest for Germany the biggest market for medicines
in the EU. The German system clearly separates three decision mod-
ules: 1. The European Medicines Agency’s assessment of the benefit
risk balance and the MA decision. 2. The Federal Joint Committee’s
assessment of the “additional benefit” of a medicine, i.e. its superior-
ity to other therapeutic options available in Germany. 3. Price negoti-
ations between marketing authorization holders and payers based
on the medical need, the size of the additional benefit and the cost
of the available alternative therapies, with potentially significant price
corrections six or twelve months after marketing.
Joint scientific advice from regulators and HTA bodies will help to
streamline development, optimize study design and support early MA
and wide patients’ access. For innovative oncology immunotherapies
particularly with potentially curative effect, PRIME and Adaptive Path-
ways may significantly facilitate and accelerate market access in the EU.
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